Free Trial

Altimmune (NASDAQ:ALT) Upgraded by The Goldman Sachs Group to Strong Sell Rating

Altimmune logo with Medical background

Altimmune (NASDAQ:ALT - Get Free Report) was upgraded by stock analysts at The Goldman Sachs Group to a "strong sell" rating in a research note issued on Thursday, Marketbeat Ratings reports.

Several other research firms also recently commented on ALT. HC Wainwright reiterated a "buy" rating and issued a $12.00 price objective on shares of Altimmune in a report on Friday, June 27th. JMP Securities decreased their price objective on Altimmune from $25.00 to $15.00 and set a "market outperform" rating on the stock in a report on Thursday. Wall Street Zen downgraded Altimmune from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. Finally, William Blair reiterated a "market perform" rating on shares of Altimmune in a report on Friday, June 27th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Altimmune has a consensus rating of "Moderate Buy" and a consensus target price of $18.20.

Get Our Latest Stock Analysis on Altimmune

Altimmune Trading Down 7.2%

Shares of NASDAQ:ALT opened at $4.40 on Thursday. The stock has a market capitalization of $356.88 million, a P/E ratio of -3.49 and a beta of 0.47. The stock's 50-day moving average price is $5.65 and its 200-day moving average price is $5.87. Altimmune has a 12-month low of $2.90 and a 12-month high of $11.16.

Altimmune (NASDAQ:ALT - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.09. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative return on equity of 65.44% and a negative net margin of 451,200.00%. During the same quarter in the previous year, the business earned ($0.34) earnings per share. As a group, research analysts predict that Altimmune will post -1.35 EPS for the current year.

Institutional Trading of Altimmune

Several large investors have recently bought and sold shares of the company. Barclays PLC boosted its position in Altimmune by 1.1% during the 4th quarter. Barclays PLC now owns 157,528 shares of the company's stock valued at $1,135,000 after acquiring an additional 1,787 shares in the last quarter. Rafferty Asset Management LLC boosted its position in shares of Altimmune by 1.3% in the 4th quarter. Rafferty Asset Management LLC now owns 157,750 shares of the company's stock worth $1,137,000 after purchasing an additional 1,964 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Altimmune by 2.0% in the 4th quarter. JPMorgan Chase & Co. now owns 102,940 shares of the company's stock worth $742,000 after purchasing an additional 2,028 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Altimmune by 1.2% in the 1st quarter. Bank of New York Mellon Corp now owns 189,000 shares of the company's stock worth $945,000 after purchasing an additional 2,162 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Altimmune by 4.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company's stock worth $247,000 after purchasing an additional 2,241 shares in the last quarter. 78.05% of the stock is owned by institutional investors.

About Altimmune

(Get Free Report)

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

Featured Stories

Analyst Recommendations for Altimmune (NASDAQ:ALT)

Should You Invest $1,000 in Altimmune Right Now?

Before you consider Altimmune, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Altimmune wasn't on the list.

While Altimmune currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines